Suzhou Novartis Pharma Technology Maps Out Next Year’s Investment Plan
This article was originally published in PharmAsia News
Executive Summary
Suzhou Novartis Pharma Technology, Novartis' investment in China focusing on R&D and production of patented active pharmaceutical ingredients, recently disclosed that it began Phase 1 trials in October. Since beginning operations early this year, the company's analytical chemistry and R&D center has brought in almost 100 local and overseas experts, engineers and researchers to develop and synthesize Novartis' innovative raw ingredients. Even during the current global economic recession, Suzhou Novartis is still adhering to its original plan of investing $50 million next year for Phase II and III projects. With a long-term development view in China, it will further pump in $30 million to expand its R&D center, adding new equipment and staff. (Click here for more - Chinese Language)